What's new? Log in Free sign up

Atossa Therapeutics (ATOS) News and press releases

Company Profile

News

From Benzinga Pro

Atossa Therapeutics Q1 EPS $(0.05) Beats $(0.06) Estimate

Atossa Therapeutics (NASDAQ:ATOS) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.06) by 16.67 percent. This is a 25 percent decrease over losses of $(0.04) per share from

Atossa Therapeutics Announces Year-End 2022 Financial Results And Provides Corporate Update; As Of December 31, 2022, We Had Cash, Cash Equivalents And Restricted Cash Of $111,000

Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in cancer, today announced financial results for the

Atossa Therapeutics And Quantum Leap Healthcare Announce New Study Arm To Evaluate (Z)-Endoxifen In The Ongoing I-SPY 2 Clinical Trial

Biotech, News, FDA, General

Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology, and Quantum Leap Healthcare Collaborative™

Press releases

From Benzinga Pro

Societal CDMO Enters Agreement With Atossa Therapeutics to Provide Clinical Trial Services (CTS) for Innovative Selective Estrogen Receptor Modulator

Press Releases, General

SAN DIEGO and GAINESVILLE, Ga., May 23, 2023 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (("Societal CDMO", NASDAQ:SCTL), a contract development and manufacturing organization (CDMO) dedicated to solving complex

Atossa Therapeutics Announces First Quarter 2023 Financial Results and Provides Corporate Update

Earnings, Press Releases

Two Phase 2 trials investigating (Z)-endoxifen in neoadjuvant setting initiated and are enrolling patientsFull enrollment of Phase 2 KARISMA mammographic breast density study expected by end of 2023Ended first quarter

Physician-Scientist Dr. Steven Quay Provides Recommendations to the United States Preventive Services Task Force on Breast Cancer Screening Policies and Practices

SEATTLE, May 11, 2023 /PRNewswire/ -- Physician-Scientist Dr. Steven Quay, MD, PhD has provided a set of recommendations to the United States Preventive Services Task Force (USPSTF) following the publication of their

Atossa to Present a Trial in Progress Poster on its Neoadjuvant Breast Cancer Phase 2 Clinical Trial, EVANGELINE, at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

News, Health Care, Analyst Ratings, Press Releases

SEATTLE, May 09, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology

Atossa Therapeutics to Participate in Tribe Public's Webinar Event "Redefining Breast Cancer Prevention and Treatment"

Health Care, Press Releases

Virtual webinar scheduled for Thursday, May 4 at 8:00 am pacific / 11:00 am easternMeet with Atossa's Founder and CEO, Steven Quay, M.D., Ph.D.Event is open to the public – registration available at

Atossa Therapeutics Announces Year-End 2022 Financial Results and Provides Corporate Update

Earnings, Press Releases

SEATTLE, March 22, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in cancer,

Atossa Therapeutics and Quantum Leap Healthcare Announce New Study Arm to Evaluate (Z)-Endoxifen in the Ongoing I-SPY 2 Clinical Trial

SEATTLE and SAN FRANCISCO, March 21, 2023 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in

Atossa to Present at the Sidoti Small-Cap Virtual Conference

SEATTLE, March 15, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in cancer,

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.